Chapter 9 206 Count 40 20 0 Trial EAP 0.00 0.25 Propensity 0.50 0.75 1.00 Figure 6: Distribution of propensity scores of patients in the vemurafenib trial and expanded access program (EAP). Posterior density Objective Response Rate EAP ProPP Trial 0.4 0.5 0.6 0.7 Figure 7: Posterior distributions of estimates of the Objective Response Rate computed using data from the trial only, expanded access program (EAP) only, or combined EAP and trial through the ProPP method. We observe that the inclusion of expanded access data to augment the active trial arm leads to an increase in precision with a similar mean parameter estimate in this specific example of vemurafenib.
RkJQdWJsaXNoZXIy MTk4NDMw